Zoetis, Inc. Class A (ZTS)

Over the past six months, Zoetis's stock price has experienced fluctuations, with a decline of 20.90% as of April 2, 2026. Key events impacting the stock include the release of Q4 and full year 2025 results, the acquisition of Neogen Corporation's animal genomics business, analyst downgrades and mixed sentiment, an activist investor proposal, concerns over Librela's safety, and market performance. Despite exceeding analysts' expectations in Q4, the stock was down 5.4% since reporting. Safety concerns regarding Librela have created a persistent overhang on the stock, leading to a 32% decline in sales. Zoetis underperformed the US Pharmaceuticals industry and the US Market over the past year.

The provided information does not explicitly detail specific demand seasonality for Zoetis's products and services. However, the company's diversified portfolio and global presence generally provide stability. Demand for certain products, such as parasiticides, might see some seasonal variations. The company's focus on innovative solutions suggests a consistent underlying demand for animal health products.

Zoetis, Inc. is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, and diagnostic products and services for livestock and companion animals. The company operates within the pharmaceutical sector, focusing on animal health and is the world's largest producer of medicine and vaccinations for pets and livestock. Its product portfolio comprises over 300 product lines across seven major categories, serving eight core species.

Zoetis has a significant global presence, marketing its products in over 100 countries and maintaining a local presence in approximately 70 countries. Operations outside the United States accounted for 50% of total revenue in 2024. The company operates 21 manufacturing facilities around the world, including nine in the U.S. across seven states. Zoetis's global headquarters are in Parsippany, New Jersey, U.S.

Zoetis generally holds a strong brand reputation as a market leader in animal health, recognized on Forbes lists. However, the company's reputation has faced challenges due to Librela safety concerns, which have led to negative press and investor skepticism. Additionally, the bird flu outbreak and Zoetis's role in addressing it could indirectly affect the perception of the livestock industry.

Zoetis's ownership structure includes institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's stock, approximately 79.14% to 92.80%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Top individual investors include David M. Polen, Terry Smith, and David Rolfe. Insiders own approximately 0.08% of the stock.